Press release from Companies
Published: 2026-02-19 08:00:00
OSLO, NORWAY – February 19, 2026: Genetic Analysis AS ("GA" or "the Company") announces that its patent application US2017/0369941 has been allowed for grant by the United States Patent and Trademark Office (USPTO). The patent, entitled "METHOD FOR PREVENTING FALSE POSITIVES IN METHODS EMPLOYING DDNTP’S", strengthens the protection of GA’s proprietary diagnostic technology. GA maintains an active patent strategy covering all major geographical markets and has previously announced approval in the EU and other countries for this patent.
CEO Ronny Hermansen comments:
”High analytical accuracy is fundamental in molecular diagnostics. This patent protects technology that reduces the risk of false-positive signals, thereby increasing the reliability of our assays. Securing protection in the U.S. strengthens our technological position in a key market and supports our long-term commercial strategy.”
The patent covers a technology that enhances the accuracy of molecular diagnostic assays by minimizing false-positive signals in systems based on DNA polymerases, ddNTPs, and fluorophores.
It addresses a source of error in DNA-based tests used to detect specific genetic sequences. The inventors showed that some reagents in these assays, and sometimes the enzyme used in the reaction, can bind to DNA in unintended ways and produce misleading signals. The invention describes practical steps to reduce these effects, such as removing or inactivating the enzyme at certain stages, adjusting reaction conditions, or redesigning the DNA components so that only the intended binding events occur. By doing this, the tests yield more accurate and more reliable results.
The patent has been approved for grant by United States Patent and Trademark Office (USPTO). The required fee has been paid and the patent is expected to be formally issued in Q1 2026. The patent family claims priority from 30 January 2015 and will be in force until 2036.
For more information, please contact:
Ronny Hermansen, CEO
E-mail: rh@genetic-analysis.com
About Genetic Analysis:
Genetic Analysis AS (GA) is a science-based diagnostic company and pioneer in the human microbiome field with more than 15 years of expertise in research and product development. The unique GA-map® platform is based on a pre-determined multiplex targets approach specialized for simultaneous analysis of a large number of bacteria in one reaction. The test results are generated by utilizing the clinically validated cutting edge GA-map® software algorithm. This enables immediate results without the need for further bioinformatics work. GA’s vision is to become the leading company for standardized gut microbiota testing worldwide, and GA is committed to help unlocking and restoring the human microbiome through its state-of-the-art technology. GA employs a team of highly qualified employees with scientific backgrounds and competence in bioinformatics, molecular biology, and bioengineering.
For more information: www.genetic-analysis.com
Interested in reading more about GA's products? Please visit ga-map.com
